IOL Chemicals Q2 FY27 Earnings Call — Analysis (NSE: IOLCP)

IOL Chemicals announced three strategic capex initiatives totaling ~₹500 Cr across Ibuprofen expansion, CDMO formulations, and specialty chemicals tolling, targeted to add 25-30% incremental top line by FY29.

17 Sept 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

FY27-FY28 Total Planned Strategic Capex ₹500 Cr . Guidance raised — incremental revenue contributio… 25% to 30% incremental top line . But walked back — Disciplined capex and future growth platform . New story: Capacity utilization and operating leverage .

Financial highlights

Guidance

Management reaffirmed FY27 revenue growth guidance of 15-20% and guided for 25-30% incremental top-line contribution by FY29 upon full project commercialization.

What management committed to

• The new Ibuprofen facility (6,000 MTPA expansion to total 18,000 MTPA) will be fully backward integrated and is expected to be commissioned by December 2027. — December 2027, FY28 Q3
• The new CDMO formulation facility (1,500 million tablets per annum) has received EU GMP certification and commercialization is expected during Q3 FY27. — Q3 FY27, FY27 Q3
• Collectively, the three announced initiatives (Ibuprofen expansion, CDMO, specialty chemical tolling) are expected to contribute an incremental 25% to around 30% to [the company's] top line over the coming years. — 25% to 30% incremental top line, over the coming years
• The Ibuprofen expansion asset turn (peak revenue to investment) is expected to be 1.75x to 2x. — 1.75x to 2x, at peak utilization (post FY28)
• The CDMO facility asset turn (peak revenue to investment) is expected to be 1x to 1.25x at approximately 90% utilization. — 1x to 1.25x, at optimum utilization
• The new Ibuprofen capacity will reach around 25% utilization in FY28, and optimal utilization (more than 80%) will be achieved in FY28-29. — 25% in FY28, >80% by FY29, FY28
• The CDMO facility will achieve optimal utilization in 18 to 24 months from commercialization (Q3 FY27). — 18-24 months, FY29
• The specialty chemical facility is being established under a long-term tolling arrangement with a leading global chemical company, providing visibility of long-term manufacturing demand. — long-term tolling arrangement, long-term
• The combined projects are expected to deliver a ROCE of more than 15% when fully implemented. — more than 15%, when fully implemented

Key themes

Strategic Capex and CDMO Forward Integration

How the narrative shifted

• Non-ibuprofen API diversification: Previously a core thread; it has been dropped entirely in favor of the new capex announcements.
• Export market expansion: The export narrative is absent; the call focused on domestic and European customer-led investments.
• Capacity utilization and operating leverage: The thread shifted from paracetamol utilization and general efficiency to the specific utilization trajectory of the new Ibuprofen and CDMO assets.
• Input cost volatility and price stability: The stable pricing narrative is reaffirmed; no new volatility concerns raised.
• Disciplined capex and future growth platform: Previously a supporting thread about modest ~₹200 Cr annual capex; now elevated and expanded with a multi-year, large-scale capex plan while retaining the 'internal accruals' discipline message.
• Chemical segment resilience: The chemical segment discussion is absent; replaced by the new specialty chemical tolling arrangement which is treated as a separate initiative.
• Regulatory progress in China: The regulatory progress thread is dropped; the call focuses on EU GMP for CDMO.
• CDMO formulations entry: Management announces a new CDMO facility with EU GMP certification, commercialization in Q3 FY27, targeting European anchor customers, seen as forward integration from existing API relationships.
• Specialty chemicals tolling partnership: Management announces a customer-led specialty chemical facility under a long-term tolling arrangement with a leading global chemical company, providing demand visibility.

Operational commentary

• Expanding Ibuprofen capacity by 6,000 MTPA to 18,000 MTPA via fully backward-integrated facility; commissioning targeted by December 2027 (Q3FY28).
• Established a new CDMO formulations facility (1,500 million tablets per annum / Direct Compressible Grade) with EU GMP certification, commercializing in Q3FY27.
• Setting up a dedicated specialty chemical facility under a long-term tolling agreement with a leading global chemical company.
• Entire ~₹500 Cr capex is funded purely via internal accruals, with ~30% already deployed across FY27-FY28.
• Greenfield project on 100-acre land is proceeding separately with regulatory approvals underway, independent of the current brownfield ₹500 Cr capex.

Analyst Q&A

• Q. Margins and specific revenue expectations for the new CDMO formulations segment

  Indicated asset turnover of 1.0x to 1.25x at ~90% utilization and stated margins would be better than API margins, but declined to give exact margin figures citing early stage.

• Q. Current pricing environment and margin expansion prospects across APIs

  Paracetamol prices have softened from peaks while Ibuprofen prices remain stable; fully backward integrated setup positions company for margin defense and potential expansion.

• Q. Clarification on whether ₹500 Cr capex is part of previously indicated ₹1,200-1,400 Cr multi-year capex

  Clarified that the ₹500 Cr capex is at the existing site, whereas the ₹1,200-1,400 Cr capex is for an upcoming greenfield facility 25-30 km away.

View source

Research and educational content only. Not investment advice.